Meet
Mariia Salova

Senior Research Scientist

Mariia Salova supports clients in market access, product commercialization, and reimbursement strategy that span a variety of healthcare sectors and stakeholders.

Mariia partners with pharmaceutical and biotechnology clients, including manufacturers in rare and ultra-rare disease space, to develop market access assessments and launch strategies to ensure successful asset commercialization. She assists clients by providing strategic guidance on product commercialization and evaluation of market dynamics shaping coverage and reimbursement throughout a product’s life cycle via primary and secondary research. She also applies her clinical background to a broad range of client projects.

Prior to joining Avalere, Mariia worked at a boutique consulting company, Apperture Health, as a market access consultant where she helped clients with commercial strategy development, the creation of evidence-based value propositions, and value communication. Additionally, Mariia has clinical experience working as a medical resident at a major oncology center in Kyiv, Ukraine, and as a medical volunteer in rural Nepal. She is also a graduate teaching assistant at The Johns Hopkins University assisting professors in shaping future healthcare business leaders.

Mariia has two medical degrees in general medicine and medical psychology from Bogomolets National Medical University of Ukraine and an MS in healthcare management from The Johns Hopkins University.

Authored Content


As the GLP-1 product market continues to expand, manufacturers must find ways to differentiate their inline and pipeline assets with new evidence and strong value story.

Disease registries can provide high-quality data and may serve as an additional resource when developing medical interventions for rare and ultra-rare diseases.

In an eBook, Avalere Health experts describe the policy, market access, and evidence landscape of rare disease in the United States and globally.

Novel approaches to newborn screening of rare diseases could shape the future of federal and state screening guidelines.

A detailed Avalere report offers insights into state-specific statutes guiding commercial payer coverage for off-label use of oncology drugs/biologics.

Stakeholders should seek to engage with RDACs to develop a better understanding of rare disease care access, treatment, and populations in different states.

A white paper explores the RNA-based therapy pipeline and how FDA classifications can influence product development, commercialization, and patient access.

In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts summarize key learnings for pharmaceutical companies to consider.

Drug repurposing offers developers an opportunity to bring treatment options to patients at a reduced cost and shortened timelines, although challenges exist.

In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts dive into access drivers and considerations in the rare disease space.

In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts provide an introduction into regulatory approaches to rare diseases.

Rare disease drug manufacturers can advance clinical development through FDA programs aimed at facilitating pipeline innovation.

Decentralized clinical trials offer the potential to democratize rare disease research, advancing drug development and improving patient experiences.

Policies within the IRA and at the FDA in response to recent litigation could influence commercialization decisions for orphan drugs and may need to be clarified by policymakers.

Increasing clinical trial diversity presents unique challenges for rare disease treatments due to population size, disease heterogeneity, and low awareness.

A diagnostic odyssey is defined as the time between when a symptom or feature of a genetic or rare disease is noted to the time when a final diagnosis is made.

Changes to rare disease policies and payers’ approaches to coverage could have significant impacts on product development, patient access, and reimbursement.